Background Antiangiogenic agents that specifically target vascular endothelial growth factor
receptor (VEGFR), such as sunitinib, have been utilized as the standard therapy for …

Sunitinib resistance is, nowadays, the major challenge for advanced renal cell carcinoma
patients. Illuminating the potential mechanisms and exploring effective strategies to …

A multiple receptor tyrosine kinase inhibitor, sunitinib, is a first-line therapy for clear cell
renal cell carcinoma (CCRCC). Unfortunately, it has the major challenges of low initial …

Sunitinib is considered a first-line therapeutic option for patients with advanced clear cell
renal cell carcinoma (ccRCC). Despite sunitinib's clinical efficacy, patients eventually …

Tyrosine kinase inhibitors (TKIs) are the most commonly used targeted therapeutics in clear-
cell renal cell carcinoma (ccRCC); however, drug resistance limits their utility and can lead …

Background Renal cell carcinoma (RCC) contributed to 403,262 new cases worldwide in
2018, which constitutes 2.2% of global cancer, nevertheless, sunitinib, one of the major …

Sunitinib is one of the most widely used targeted therapeutics for renal cell carcinoma
(RCC), but acquired resistance against targeted therapies remains a major clinical …

Currently, renal cell carcinoma (RCC) is the most prevalent type of kidney cancer. Targeted
therapy has replaced radiation therapy and chemotherapy as the main treatment option for …

Resistance in clear cell renal cell carcinoma (ccRCC) against sunitinib is a multifaceted
process encompassing numerous molecular aberrations. This induces clinical …

Background Renal cell carcinoma (RCC) is a highly vascular tumor and patients with low
risk metastatic RCC of clear-cell histological sub-type (mccRCC) are treated with tyrosine …